Tenapanor
Brand Names: Xphozah 20 Mg, Xphozah 30 Mg, Xphozah 10 Mg
Methodology & AI Transparency ⓘ
Tenapanor Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Tenapanor is an FDA-registered prescription sodium-hydrogen exchanger 3 inhibitor (oral-route administration) manufactured/labeled by Ardelyx, Inc.
- 2 Real-world patient consensus: 91% patient "Worth It" rating across 11 anonymous logs for Tenapanor (RxNorm RXN-73154120-2723).
- 3 Typical cash cost range: Dispensing cost comparison spans $27.13 mail/discount cash up to $66.47 uninsured retail (federal NADAC $0.4600).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Tenapanor): nausea (7.9%), headache (6.8%), dizziness (6%).
Ask our AI Specialists anything about Tenapanor
Tenapanor Mechanism, CYP450 Pathways & DailyMed Monograph
Tenapanor is an FDA-registered prescription sodium-hydrogen exchanger 3 inhibitor (oral-route administration) manufactured/labeled by Ardelyx, Inc. under National Drug Code 73154-120, 73154-130, supplied in 20 mg/1 Tablet, Film Coated and 30 mg/1 Tablet, Film Coated for physician-directed therapeutic management.
Pharmacologically, Tenapanor functions within the Sodium-Hydrogen Exchanger 3 Inhibitor class via oral-route delivery (20 mg/1 Tablet, Film Coated and 30 mg/1 Tablet, Film Coated), modulating target cellular receptors or enzymatic cascades while undergoing physiological hepatorenal clearance documented under FDA NDC 73154-120, 73154-130 (manufactured/labeled by Ardelyx, Inc.).
Pharmacokinetic profiling of Tenapanor demonstrates an elimination half-life of Biphasic clearance with 8–21 hr terminal t½ under Tenapanor maintenance with Systemic oral bioavailability of roughly 48%–60% following first-pass transit systemic bioavailability; clearance proceeds via hepatic enzymatic processing and renal clearance proportional to creatinine clearance (tenapanor), reaching clinical onset within initial pharmacodynamic onset within 1–2 hrs (peak cmax) for tenapanor.
Titration schedules for Tenapanor (20 mg/1 Tablet, Film Coated → 30 mg/1 Tablet, Film Coated → 10 mg/1 Tablet, Film Coated) require excluding known hypersensitivity to tenapanor or structurally related sodium-hydrogen exchanger 3 inhibitor compounds; concomitant contra-labeled cyp/transporter therapies during active tenapanor administration; real-world patient logs highlight nausea (7.9% of reports), headache (6.8% of reports), dizziness (6% of reports) alongside a 91.00% Worth-It consensus.
Avoid overlapping sodium-hydrogen exchanger 3 inhibitor prescriptions alongside Tenapanor to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Tenapanor dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Tenapanor or structurally related sodium-hydrogen exchanger 3 inhibitor compounds
- Concomitant contra-labeled CYP/transporter therapies during active Tenapanor administration
Logged Side-Effect Incidence (11 Reports)
Tenapanor Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Tenapanor)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete: What a 1,382-Participant Study Found Tenapanor was observed to improve abdominal symptoms independent of its effect on bowel symptoms in adults with IBS-C. Digestive diseases (Basel, Switzerland) • 2025-01-15 • Phase III Randomized Trial | N = 1,382 | 96/100 | PMID 39701047 ↗ |
| New Insights on Safety and real-world benefits of Tenapanor for Long-term Serum Phosphate Control: What a 423-Participant Study Found Tenapanor reduced serum phosphate concentrations and maintained control of serum phosphate in participants receiving maintenance dialysis, with an acceptable safety and tolerability profile. Kidney360 • 2021-10-28 • Phase III Randomized Trial | N = 423 | 93/100 | PMID 35372979 ↗ |
| New Insights on Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With: What a 293-Participant Study Found Of the 620 randomized patients with IBS-C, 593 (95.6%) were included in the intention-to-treat analysis set (tenapanor: n = 293; placebo: n = 300) and 481 patients (77.6%) completed the 26-week treatment period. The American journal of gastroenterology • 2021-06-01 • Phase III Randomized Trial | N = 293 | 93/100 | PMID 33337659 ↗ |
| New Insights on Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for: What a 236-Participant Study Found A dual-mechanism treatment using both tenapanor and phosphate binders improved control of hyperphosphatemia in patients undergoing maintenance dialysis compared with phosphate binders alone. Journal of the American Society of Nephrology : JASN • 2021-06-01 • Phase III Randomized Trial | N = 236 | 88/100 | PMID 33766811 ↗ |
| Can This Approach Help? Inside the Latest Research on Patient characteristics associated with the need for high doses of tenapanor The original clinical trials were registered at ClinicalTrials.gov under the identifiers NCT04767581, NCT04766398, and NCT04766385. PloS one • 2026-01-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42664364 ↗ |
Tenapanor Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.4600/unit (~$13.80/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $66.47 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 11 Anonymous DotMD Community Micro-Logs | $27.13 / mo | View logs ↓ |
Tenapanor Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Tenapanor RxNorm Concept ID | RXN-73154120-2723 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.4600 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $66.47 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $27.13 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 91.00% Worth It (11 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Tenapanor Patient Community, Cohort Filters & Dosage Logs
Deterministic Tenapanor reference combining NIH RxNorm (RXN-73154120-2723), Medicaid NADAC ($0.4600/unit), and anonymous cohort outcomes (91% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Tenapanor community threads and patient logs by age, biological sex, dosage, and treatment duration.